IgG4 antibodies and cancer-associated inflammation: Insights into a novel mechanism of immune escape

OncoImmunology

Volumn 2, Issue 7, 2013, Pages

  Karagiannis, Panagiotis ^a   Gilbert, Amy E ^a   Nestle, Frank O ^a   Karagiannis, Sophia N ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antibody effector functions; B cells; Cancer inflammation; FcVRI; IgG4; IL 10; Immune escape; Melanoma; VEGF

Indexed keywords

CANCER ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 21; INTERLEUKIN 4; TUMOR ANTIGEN; VASCULOTROPIN;

ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELL ACTIVATION; CELL FUNCTION; CELL INFILTRATION; CELL PROLIFERATION; CELL SURFACE; CHRONIC INFLAMMATION; CYTOKINE RELEASE; DISEASE ASSOCIATION; EFFECTOR CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCYTOTOXICITY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE FUNCTION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MEMORY CELL; MOLECULAR MECHANICS; MONOCYTE; POLARIZATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; SOMATIC HYPERMUTATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

EID: 84886943786     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24889     Document Type: Article

References (10)

1. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 2013; 339:286-91; PMID:23329041; http://dx.doi.org/10.1126/science.1232227
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
3. Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I, Karbach J, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187:1349-54; PMID:9547346; http://dx.doi.org/10.1084/ jem.187.8.1349
4. Gilbert AE, Karagiannis P, Dodev T, Koers A, Lacy K, Josephs DH, et al. Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. PLoS One 2011; 6:e19330; PMID:21559411; http://dx.doi.org/10.1371/journal. pone.0019330
5. Cipponi A, Mercier M, Seremet T, Baurain JF, Théate I, van den Oord J, et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res 2012; 72:3997-4007; PMID:22850419; http://dx.doi.org/10.1158/0008- 5472.CAN-12-1377
6. Lindner S, Dahlke K, Sontheimer K, Hagn M, Kaltenmeier C, Barth TF, et al. Interleukin 21-Induced Granzyme B-Expressing B Cells Infiltrate Tumors and Regulate T Cells. Cancer Res 2013; 73:2468-79; PMID:23384943; http://dx.doi.org/10.1158/0008- 5472.CAN-12-3450
7. Daveau M, Pavie-Fischer J, Rivat L, Rivat C, Ropartz C, Peter HH, et al. IgG4 subclass in malignant melanoma. J Natl Cancer Inst 1977; 58:189-92; PMID:833869
8. Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest 2013; 123:1457-74; PMID:23454746; http://dx.doi. org/10.1172/JCI65579
9. Mancardi DA, Albanesi M, Jönsson F, Iannascoli B, Van Rooijen N, Kang X, et al. The high-affinity human IgG receptor Fc?RI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy. Blood 2013; 121:1563-73; PMID:23293080; http://dx.doi.org/10.1182/blood-2012-07-442541
10. Harada K, Shimoda S, Kimura Y, Sato Y, Ikeda H, Igarashi S, et al. Significance of immunoglobulin G4 (IgG4)-positive cells in extrahepatic cholangiocarcinoma: molecular mechanism of IgG4 reaction in cancer tissue. Hepatology 2012; 56:157-64; PMID:22290731; http://dx.doi.org/10.1002/hep.25627